Cargando…
Response to “Data confusion” and “New data on the safety of IV iron -- but why the discrepancy with FIND-CKD?”: Should we REVOKE the initial use of IV iron or FIND CKD to spare ESA
Autor principal: | Agarwal, Rajiv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692379/ https://www.ncbi.nlm.nih.gov/pubmed/26649665 http://dx.doi.org/10.1038/ki.2015.304 |
Ejemplares similares
-
Bone marrow macrophage iron content and sideroblast count in iron- and ESA-naïve patients with CKD-related anemia
por: Capusa, Cristina, et al.
Publicado: (2023) -
Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial
por: Gaillard, Carlo A., et al.
Publicado: (2016) -
Management of anaemia in CKD—the relative importance of erythropoietin and iron
por: Agarwal, Rajiv
Publicado: (2011) -
Anemia and Iron Deficiency in Children with Chronic Kidney Disease (CKD): Data from the Know-Ped CKD Study
por: Lee, Keum Hwa, et al.
Publicado: (2019) -
Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial
por: Roger, Simon D., et al.
Publicado: (2017)